jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
International Journal of Pharmaceutical InvestigationNOW IN
Review

Metabolism of mRNA Therapeutics: Insights into Pharmacokinetics and Toxicology

Yogita Shinde1★, Tanishka Prakash Sharma1, Archana Shaha1, Rakesh Chaudhari2, Rashmi Rajeghorpade3, Dipali Talele1, Chitrali Talele4★ Corresponding author

  1. 1Department of Pharmaceutics, Vishwakarma University, School of Pharmacy, Pune, Maharashtra, INDIA.
  2. 2Department of Mechanical Engineering, Pandit Deendayal Energy University, Gandhinagar, Gujarat, INDIA.
  3. 3Department of Qualtiy Assurance, Pioneer Pharmacy College, Sayajipura, Vadodara, Gujarat, INDIA.
  4. 4Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara, Gujarat, INDIA.

CORRESPONDENCE

Yogita Shinde

Mrs. Yogita Shinde Department of Pharmaceutics, Vishwakarma University, School of Pharmacy, Pune, Maharashtra, INDIA.

galandeyogita@gmail.com

Received: 09-08-2025; Revised: 28-10-2025; Accepted: 14-12-2025.

Volume 16, Issue 2 · pp. 517–522 · PUBLISHED Apr-Jun 2026 · DOI: 10.5530/ijpi.20260539

View on IJPI original site ↗

ABSTRACT

Messenger RNA (mRNA) therapies are a groundbreaking treatment for various conditions, including infectious diseases, cancer, and genetic disorders. This review examines the processing of mRNA therapeutics in the body, focusing on pharmacokinetics, cellular handling, and potential toxicity. It highlights the importance of delivery methods, immune responses, and mRNA stability for effective treatment. Additionally, it addresses challenges like unintended effects and long-term safety, while proposing strategies to enhance mRNA stability and reduce toxicity. Ultimately, it provides insights into how understanding mRNA metabolism can support the future development of these therapies.

KEYWORDS

0% READ

FULL TEXT

INTRODUCTION

mRNA therapies are transforming healthcare by enabling cells to produce disease-fighting proteins. Unlike traditional medications, they allow the body to generate therapeutic proteins useful for vaccines, cancer treatment, and genetic disorders. COVID-19 vaccines use mRNA to trigger immune responses, while in cancer, mRNA targets tumor antigens, and for genetic conditions, it aids in restoring essential proteins. Understanding the absorption, distribution, metabolism, and elimination of mRNA is vital for ensuring its safety and effectiveness (Karikó et al., 2008).

mRNA metabolism: an overview

mRNA consists of key components: the 5′ cap, UTRs, ORF, and poly(A) tail, which affect its stability, translation, and which influence its stability, translation efficiency, and therapeutic use, as illustrated in Figure 1 (Mockey 2006; Henderson, 2021; Grier, 2016). The 5′cap, a modified guanine, prevents degradation and aids translation; improved analogs can enhance capping efficiency to 95%, boosting stability and protein production, as demonstrated in Figure 2. The poly(A) tail, consisting of approximately 100–300 adenine residues, also increases stability and can be optimized for better performance (Holtkamp, 2006; Schlake 2012). UTRs regulate translation and can be tailored for better efficiency and tissue-specific expression. While many mRNAs use α- or β-globin UTRs, further optimization can increase yield (Holtkamp, 2006; Vaidyanathan 2018; Ross and Sullivan, 1985).

Figure 1: Messenger RNA (mRNA) (Chavda, 2021).
Figure 2: Post-transcriptional capping (left) is a two-step enzymatic process, whereas co-transcriptional capping (right) adds a cap analog during transcription using an enzyme from in vitro transcription (Hu, 2020).

Modified nucleosides such as 1-methylpseudouridine and N1-methyladenosine boost mRNA stability and lower immune activation. N1-methyladenosine aids in evading RIG-I, which enhances delivery and diminishes the immune response-crucial for progressing mRNA therapies for infections, cancer, and genetic disorders (Pascolo, 2021; Sahin et al., 2014; Kowalski, 2019).

Degradation pathways

Endogenous enzymes control mRNA stability and degradation. Deadenylases shorten the poly(A) tail to start decay, while decapping enzymes DCP1 and DCP2 remove the 5' cap, resulting in degradation by the exosome complex, represented in Figure 3 (Karikó, 2011). Eukaryotic mRNAs degrade from the 3' to 5' end after the poly(A) tail is removed, which is crucial for mRNA stability and translation (Muhlrad et al., 1994; Muhlrad et al., 1995).

Figure 3: Eukaryotes degrade mRNA to regulate gene expression and control protein production in response to changing conditions (Fischer, 2003).

In yeast, blocking 5' to 3' decay causes accumulation of 3' PGK1 mRNA fragments, suggesting a shift to 3' to 5' decay. Similar results in oat phytochrome A mRNA indicate this process is conserved (Higgs and Colbert, 1994). The exact roles of exonucleases and endonucleases remain unclear. Notably, some mRNAs display stability without a poly(A) tail, indicating that other factors contribute to stability (Decker and Parker, 1993; Dujon, 1994).

Pharmacokinetics of mRNA therapeutics

Delivery systems and tissue targeting

mRNA delivery efficiency is greatly influenced by the method used, with Lipid Nanoparticles (LNPs) being the most common. LNPs enter cells via endocytosis, releasing mRNA for protein synthesis. Advanced systems like polymeric and hybrid lipid-polymer nanoparticles enhance targeting, while polymeric carriers show promise for lung treatments in asthma and COPD (Hou, 2021; Riley, 2021).

Modern RNA-loaded Lipid Nanoparticles (LNPs), evolved from 1960s liposomes, consist of cholesterol, ionizable lipids, and stealth lipids. Their core features structural lipids, while neutral phospholipids stabilize the bilayer and cholesterol enhances RNA delivery efficiency (Riley, 2021; Ad, 1965; Briuglia, 2015; Gregoriadis and Davis, 1979; Kirby et al., 1980; Malone et al., 1989).

Stability and protein translation

mRNA stability is crucial for its longevity and protein production, especially in therapies. Innovations like Clean Cap, a 5' cap analog, enhance stability, translation efficiency, and degradation resistance, leading to a longer half-life and increased protein synthesis (Wu, 2024; Rouf, 2022). Modifying UTRs boosts stability, aiding single-dose vaccines like Zika by enhancing immune responses and reducing dosage (Richner, 2017; Hengelbrock, 2023). PERSIST-seq involves introducing mRNA pools into HEK293T cells, separating translating from non-translating mRNAs with sucrose gradients. RT-PCR and Illumina sequencing assess translation efficiency, with polysome-associated mRNAs indicating active translation (Kozak, 1994; Babendure, 2006). Early results showed clear translation differences between ActB mRNA and scrambled UTR controls (Osuna, 2017).

Clearance pathways

Post-translation, mRNA breaks down into nucleotides, regulating gene expression and preventing protein accumulation. These nucleotides can be reused or converted into essential metabolites, with excess eliminated to maintain balance (Hoecke and Roose, 2019; Stephenson and Zamecnik, 1978). Clearance mainly involves the kidneys and liver. The kidneys filter waste and salts into urine, while the liver transforms substances into less harmful or water-soluble forms (Sharma and Watts, 2015; Dammes and Peer, 2020; Holland, 2024). The liver produces proteins, regulates glucose storage, and secretes bile for fat digestion, all vital for drug development (Holland, 2024). Understanding nucleotide metabolism aids drug optimization, improving efficacy and safety by balancing clearance rates to reduce dosing frequency and toxicity, while enhancing stability and bioavailability (Watson and Crick, 1953).

Toxicological implications

Immunogenic responses

Unaltered mRNA activates receptors like TLR3, TLR7, TLR8, and RIG-I, causing inflammation or autoimmune responses. Modified nucleosides, such as 5-methylcytidine and pseudouridine, enhance stability, reduce immune detection, and improve translation (Moles, 2019; Mu and Hur, 2021). Enhanced delivery boosts safety and effectiveness in vaccines, cancer treatments, and genetic therapies (Haque, 2020; Heine et al., 2021). Continuous research focuses on improving carriers and minimizing immune reactions (Corbett, 2020; Maruggi, 2019).

Cumulative toxicity

The use of mRNA treatments, like vaccines and gene therapy, raises concerns about Lipid Nanoparticles (LNPs) accumulating in the liver and spleen, which are crucial for detoxification and immune function (Fang, 2022; Hu, 2020; Janas, 2018; Lv, 2006; Monnery, 2017). LNP accumulation can lead to lasting toxicity. To mitigate this, researchers are creating biodegradable carriers that decompose into safe by products, enhancing safety and delivery (Fischer, 2003; Moghimi, 2005; Kedmi, 2010; Soenen, 2009).

siRNAs can also induce immune responses and toxicity, complicating their clinical use (Dokka, 2000). Pattern Recognition Receptors (PRRs), such as Toll-like Receptors (TLRs), trigger cytokine release, inflammation, and reduced effectiveness (Dokka, 2000). Unmodified siRNAs can cause unintended effects, stress, and cell death, and certain delivery methods may heighten immune activation (Toh, 2009; Horie, 2013).

Potential integration risks

mRNA plays a crucial role in protein synthesis and does not change the host genome, making it suitable for vaccines and treatments (Wolff, 1990). Its stability and translation are influenced by the sequence, cell type, and surrounding environment (Boczkowski, 1996). Since 1990, the use of exogenous mRNA has led to significant advancements in therapeutic and preventive molecular medicine (Hoerr, 2000).

RNA technologies currently facilitate cancer immunotherapy, protein replacement, genome editing, and vaccine development (Hu, 2020). mRNA is responsible for encoding proteins that can fix mutations or enhance immune responses, while siRNA is used to silence detrimental genes associated with diseases (Chavda, 2021). To increase safety, current designs incorporate degradation signals to manage the lifespan of mRNA (Sahin, 2014), striking a balance between effectiveness and risk (Kreiter, 2016). Ongoing studies are focused on improving the performance of mRNA therapies (Zheng, 2000; Vader, 2016).

Emerging strategies to optimize mRNA therapeutics

Advanced delivery systems

Exosomes are natural vesicles that carry biomolecules such as mRNA, providing biocompatibility and targeted gene delivery for cancer with little effect on healthy cells, as depicted in Figure 4 (Sedic, 2018). Dendritic polymers, also known as dendrimers, are branched nanocarriers that can deliver small molecules, proteins, and nucleic acids with great accuracy and absorption. Merging these two systems could improve the effectiveness and safety of therapies, especially in cancer treatment (Li, 2014; Funabiki, 2014).

Figure 4: There are various methods for packing cargo into exosomes (Van Hoecke and Roose, 2019).

Bioconjugation technologies

Attaching specific molecules to mRNA delivery systems enhances accuracy by focusing on particular tissues and minimizing systemic side effects. Lipid Nanoparticles (LNPs), which are frequently utilized for mRNA delivery, can be altered with ligands such as galactose to specifically target liver cells through receptor recognition. This approach is particularly beneficial for addressing rare liver-related metabolic disorders by delivering mRNA that encodes functional proteins directly to hepatocytes, thereby restoring function and alleviating symptoms along with off-target effects (Ramírez-Cortés and Ménová, 2025).

Crispr-driven optimization

Attaching specific molecules to mRNA delivery systems enhances the accuracy and effectiveness of mRNA therapeutics by allowing targeted delivery to specific tissues, which helps to minimize side effects from systemic distribution. Lipid Nanoparticles (LNPs) are a prominent delivery method, encapsulating mRNA and facilitating cellular entry. When modified with targeting ligands such as galactose-recognized by liver cell receptors-LNPs improve liver-specific delivery. This is particularly beneficial for treating liver-related metabolic disorders resulting from genetic mutations. The targeted delivery of mRNA that encodes functional proteins can restore liver function, alleviate symptoms, and reduce necessary dosages, thereby minimizing off-target effects (Ramírez-Cortés and Ménová, 2025).

CONCLUSION

mRNA therapies mark a significant breakthrough in the treatment of infectious diseases and genetic disorders. Their effectiveness depends on a solid grasp of pharmacokinetics, processing, and possible toxicity. Progress in chemical modifications, delivery methods, and translation efficiency has enhanced stability, minimized immune responses, and allowed for targeted actions. Their applications include vaccines, cancer therapies, and rare genetic disorders, although concerns regarding long-term safety and immune activation remain and immune activation. Emerging tools such as exosome-based delivery and CRISPR systems further expand therapeutic potential. Ongoing collaboration across disciplines is crucial to ensure a balance between safety and effectiveness in future mRNA therapies.

REFERENCES

As published

Showing references and in-text citations exactly as published.

  1. 1.Boczkowski, D.; Nair, S. K.; Snyder, D.; Gilboa, E.. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. The Journal of Experimental Medicine. 1996;184(2):465–472. https://doi.org/10.1084/jem.184.2.465DOIGOOGLE SCHOLAR
  2. 2.Briuglia, M.-L.; Rotella, C.; McFarlane, A.; Lamprou, D. A.. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Delivery and Translational Research. 2015;5(3):231–242. https://doi.org/10.1007/s13346-015-0220-8DOIGOOGLE SCHOLAR
  3. 3.Chavda, V. P.; Hossain, M. K.; Beladiya, J.; Apostolopoulos, V.. Nucleic acid vaccines for COVID-19: A paradigm shift in the vaccine development arena. Biologics. 2021;1(3):337–356. https://doi.org/10.3390/biologics1030020DOIGOOGLE SCHOLAR
  4. 4.Corbett, K. S.; Edwards, D. K.; Leist, S. R.; Abiona, O. M.; Boyoglu-Barnum, S.; Gillespie, R. A. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. https://doi.org/10.1038/s41586-020-2622-0DOIGOOGLE SCHOLAR
  5. 5.Decker, C. J.; Parker, R.. A turnover pathway for both stable and unstable mRNAs in yeast: Evidence for a requirement for deadenylation. Genes and Development. 1993;7(8):1632–1643. https://doi.org/10.1101/gad.7.8.1632DOIGOOGLE SCHOLAR
  6. 6.Dokka, S.; Toledo, D.; Shi, X.; Castranova, V.; Rojanasakul, Y.. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharmaceutical Research. 2000;17(5):521–525. https://doi.org/10.1023/A:1007504613351DOIGOOGLE SCHOLAR
  7. 7.Dörrie, J.; Schaft, N.; Schuler, G.; Schuler-Thurner, B.. Therapeutic cancer vaccination with ex vivo RNA-transfected dendritic cells-An update. Pharmaceutics. 2020;12(2):Article 92. https://doi.org/10.3390/pharmaceutics12020092DOIGOOGLE SCHOLAR
  8. 8.Dujon, B.; Alexandraki, D.; André, B.; Ansorge, W.; Baladron, V.; Ballesta, J. P. G. et al. Complete DNA sequence of yeast chromosome XI. Nature. 1994;369(6479):371–378. https://doi.org/10.1038/369371a0DOIGOOGLE SCHOLAR
  9. 9.Fang, E.; Liu, X.; Li, M.; Zhang, Z.; Song, L.; Zhu, B. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy. 2022;7(1):Article 94. https://doi.org/10.1038/s41392-022-00950-yDOIGOOGLE SCHOLAR
  10. 10.Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T.. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24(7):1121–1131. https://doi.org/10.1016/S0142-9612(02DOIGOOGLE SCHOLAR
  11. 11.Funabiki, M.; Kato, H.; Miyachi, Y.; Toki, H.; Motegi, H.; Inoue, M. et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity. 2014;40(2):199–212. https://doi.org/10.1016/j.immuni.2013.12.014DOIGOOGLE SCHOLAR
  12. 12.Gregoriadis, G.; Davis, C.. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochemical and Biophysical Research Communications. 1979;89(4):1287–1293. https://doi.org/10.1016/0006-291X(79DOIGOOGLE SCHOLAR
  13. 13.Grier, A. E.; Burleigh, S.; Sahni, J.; Clough, C. A.; Cardot, V.; Choe, D. C. et al. pEVL: A linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences. Molecular Therapy. Nucleic Acids. 2016;5(4):e306. https://doi.org/10.1038/mtna.2016.21DOIGOOGLE SCHOLAR
  14. 14.Haque, A. A.; Weinmann, P.; Biswas, S.; Handgretinger, R.; Mezger, M.; Kormann, M. S. D. et al. RNA ImmunoGenic Assay: Simple method for detecting immunogenicity of in vitro transcribed mRNA. Advances in Cell and Gene Therapy. 2020;3(2):e79. https://doi.org/10.1002/acg2.79DOIGOOGLE SCHOLAR
  15. 15.Heine, A.; Juranek, S.; Brossart, P.. Clinical and immunological effects of mRNA vaccines in malignant diseases. Molecular Cancer. 2021;20(1):Article 52. https://doi.org/10.1186/s12943-021-01339-1DOIGOOGLE SCHOLAR
  16. 16.Henderson, J. M.; Ujita, A.; Hill, E.; Yousif-Rosales, S.; Smith, C.; Ko, N. et al. Cap 1 messenger RNA synthesis with co‐transcriptional cleancap® analog by in vitro transcription. Current Protocols. 2021;1(2):e39. https://doi.org/10.1002/cpz1.39DOIGOOGLE SCHOLAR
  17. 17.Hengelbrock, A.; Schmidt, A.; Helgers, H.; Vetter, F. L.; Strube, J.. Scalable mRNA machine for regulatory approval of variable scale between 1000 clinical doses to 10 million manufacturing scale doses. Processes. 2023;11(3):745. https://doi.org/10.3390/pr11030745DOIGOOGLE SCHOLAR
  18. 18.Higgs, D. C.; Colbert, J. T.. Oat phytochrome A mRNA degradation appears to occur via two distinct pathways. The Plant Cell. 1994;6(7):1007–1019. https://doi.org/10.1105/tpc.6.7.1007DOIGOOGLE SCHOLAR
  19. 19.Hoerr, I.; Obst, R.; Rammensee, H. G.; Jung, G.. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology. 2000;30(1):1–7. https://doi.org/10.1002/1521-4141(200001DOIGOOGLE SCHOLAR
  20. 20.Holland, R.; Lam, K.; Jeng, S.; McClintock, K.; Palmer, L.; Schreiner, P. et al. Silicon ether ionizable lipids enable potent mRNA lipid nanoparticles with rapid tissue clearance. ACS Nano. 2024;18(15):10374–10387. https://doi.org/10.1021/acsnano.3c09028DOIGOOGLE SCHOLAR
  21. 21.Holtkamp, S.; Kreiter, S.; Selmi, A.; Simon, P.; Koslowski, M.; Huber, C. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017. https://doi.org/10.1182/blood-2006-04-015024DOIGOOGLE SCHOLAR
  22. 22.Horie, M.; Kobayashi, Y.; Suzuki, Y.; Tomonaga, K.. Comprehensive analysis of endogenous bornavirus-like elements in eukaryote genomes. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2013;368(1626):Article 20120499. https://doi.org/10.1098/rstb.2012.0499DOIGOOGLE SCHOLAR
  23. 23.Hou, X.; Zaks, T.; Langer, R.; Dong, Y.. Lipid nanoparticles for mRNA delivery. Nature Reviews. Materials. 2021;6(12):1078–1094. https://doi.org/10.1038/s41578-021-00358-0DOIGOOGLE SCHOLAR
  24. 24.Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y. et al. Therapeutic siRNA: State of the art. Signal Transduction and Targeted Therapy. 2020;5(1):Article 101. https://doi.org/10.1038/s41392-020-0207-xDOIGOOGLE SCHOLAR
  25. 25.Janas, M. M.; Schlegel, M. K.; Harbison, C. E.; Yilmaz, V. O.; Jiang, Y.; Parmar, R. et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nature Communications. 2018;9(1):Article 723. https://doi.org/10.1038/s41467-018-02989-4DOIGOOGLE SCHOLAR
  26. 26.Karikó, K.; Muramatsu, H.; Ludwig, J.; Weissman, D.. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research. 2011;39(21):e142–e142. https://doi.org/10.1093/nar/gkr695DOIGOOGLE SCHOLAR
  27. 27.Kedmi, R.; Ben-Arie, N.; Peer, D.. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials. 2010;31(26):6867–6875. https://doi.org/10.1016/j.biomaterials.2010.05.027DOIGOOGLE SCHOLAR
  28. 28.Kirby, C.; Clarke, J.; Gregoriadis, G.. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. The Biochemical Journal. 1980;186(2):591–598. https://doi.org/10.1042/bj1860591DOIGOOGLE SCHOLAR
  29. 29.Kowalski, P. S.; Rudra, A.; Miao, L.; Anderson, D. G.. Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Molecular Therapy. 2019;27(4):710–728. https://doi.org/10.1016/j.ymthe.2019.02.012DOIGOOGLE SCHOLAR
  30. 30.Kozak, M.. Features in the 5′ non-coding sequences of rabbit α and β-globin mRNAs that affect translational efficiency. Journal of Molecular Biology. 1994;235(1):95–110. https://doi.org/10.1016/S0022-2836(05DOIGOOGLE SCHOLAR
  31. 31.Kreiter, S.; Diken, M.; Pascolo, S.; Nair, S. K.; Thielemans, K. M.; Geall, A.. RNA vaccination therapy: Advances in an emerging field. Journal of Immunology Research. 2016;2016:Article 9703914. https://doi.org/10.1155/2016/9703914DOIGOOGLE SCHOLAR
  32. 32.Li, F.; Nellåker, C.; Sabunciyan, S.; Yolken, R. H.; Jones-Brando, L.; Johansson, A.-S. et al. Transcriptional derepression of the ERVWE1 locus following influenza A virus infection. Journal of Virology. 2014;88(8):4328–4337. https://doi.org/10.1128/JVI.03628-13DOIGOOGLE SCHOLAR
  33. 33.Lindel, F.; Dodt, C. R.; Weidner, N.; Noll, M.; Bergemann, F.; Behrendt, R. et al. TraFo-CRISPR: Enhanced genome engineering by transient foamy virus vector-mediated delivery of CRISPR/Cas9 components. Molecular Therapy. Nucleic Acids. 2019;18:708–726. https://doi.org/10.1016/j.omtn.2019.10.006DOIGOOGLE SCHOLAR
  34. 34.Litzinger, D. C.; Brown, J. M.; Wala, I.; Kaufman, S. A.; Van, G. Y.; Farrell, C. L. et al. Fate of cationic liposomes and their complex with oligonucleotive in vivo. Biochimica et Biophysica Acta. 1996;1281(2):139–149. https://doi.org/10.1016/0005-2736(95DOIGOOGLE SCHOLAR
  35. 35.Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J.. Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release. 2006;114(1):100–109. https://doi.org/10.1016/j.jconrel.2006.04.014DOIGOOGLE SCHOLAR
  36. 36.Malone, R. W.; Felgner, P. L.; Verma, I. M.. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(16):6077–6081. https://doi.org/10.1073/pnas.86.16.6077DOIGOOGLE SCHOLAR
  37. 37.Manfredonia, I.; Incarnato, D.. Structure and regulation of coronavirus genomes: State-of-the-art and novel insights from SARS-CoV-2 studies. Biochemical Society Transactions. 2021;49(1):341–352. https://doi.org/10.1042/BST20200670DOIGOOGLE SCHOLAR
  38. 38.Marasca, F.; Sinha, S.; Vadalà, R.; Polimeni, B.; Ranzani, V.; Paraboschi, E. M. et al. LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion. Nature Genetics. 2022;54(2):180–193. https://doi.org/10.1038/s41588-021-00989-7DOIGOOGLE SCHOLAR
  39. 39.Martier, R. M.. Therapeutic RNAi-based gene therapy for neurodegenerative disorders: Slowing. Neuropathology. 2016;30:103–112.GOOGLE SCHOLAR
  40. 40.Maruggi, G.; Zhang, C.; Li, J.; Ulmer, J. B.; Yu, D.. mRNA as a transformative technology for vaccine development to control infectious diseases. Molecular Therapy. 2019;27(4):757–772. https://doi.org/10.1016/j.ymthe.2019.01.020DOIGOOGLE SCHOLAR
  41. 41.Moghimi, S. M.; Symonds, P.; Murray, J. C.; Hunter, A. C.; Debska, G.; Szewczyk, A.. A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy. Molecular Therapy. 2005;11(6):990–995. https://doi.org/10.1016/j.ymthe.2005.02.010DOIGOOGLE SCHOLAR
  42. 42.Moles, E.; Kavallaris, M.; Fernàndez-Busquets, X.. Modeling the distribution of diprotic basic drugs in liposomal systems: Perspectives on malaria nanotherapy. Frontiers in Pharmacology. 2019;10:Article 1064. https://doi.org/10.3389/fphar.2019.01064DOIGOOGLE SCHOLAR
  43. 43.Monnery, B. D.; Wright, M.; Cavill, R.; Hoogenboom, R.; Shaunak, S.; Steinke, J. H. G. et al. Cytotoxicity of polycations: Relationship of molecular weight and the hydrolytic theory of the mechanism of toxicity. International Journal of Pharmaceutics. 2017;521(1–2):249–258. https://doi.org/10.1016/j.ijpharm.2017.02.048DOIGOOGLE SCHOLAR
  44. 44.Mu, X.; Hur, S.. Immunogenicity of in vitro-transcribed RNA. Accounts of Chemical Research. 2021;54(21):4012–4023. https://doi.org/10.1021/acs.accounts.1c00521DOIGOOGLE SCHOLAR
  45. 45.Muhlrad, D.; Decker, C. J.; Parker, R.. Deadenylation of the unstable mRNA encoded by the yeast MFA2 gene leads to decapping followed by 5′→3′ digestion of the transcript. Genes and Development. 1994;8(7):855–866. https://doi.org/10.1101/gad.8.7.855DOIGOOGLE SCHOLAR
  46. 46.Muhlrad, D.; Decker, C. J.; Parker, R.. Turnover mechanisms of the stable yeast PGK1 mRNA. Molecular and Cellular Biology. 1995;15(4):2145–2156. https://doi.org/10.1128/MCB.15.4.2145DOIGOOGLE SCHOLAR
  47. 47.Osuna, B. A.; Howard, C. J.; Kc, S.; Frost, A.; Weinberg, D. E.. In vitro analysis of RQC activities provides insights into the mechanism and function of CAT tailing. eLife. 2017;6:Article e27949. https://doi.org/10.7554/eLife.27949DOIGOOGLE SCHOLAR
  48. 48.Pardi, N.; Krammer, F.. mRNA vaccines for infectious diseases-Advances, challenges and opportunities. Nature Reviews. Drug Discovery. 2024;23(11):838–861. https://doi.org/10.1038/s41573-024-01042-yDOIGOOGLE SCHOLAR
  49. 49.Pardi, N.; Tuyishime, S.; Muramatsu, H.; Kariko, K.; Mui, B. L.; Tam, Y. K. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release. 2015;217:345–351. https://doi.org/10.1016/j.jconrel.2015.08.007DOIGOOGLE SCHOLAR
  50. 50.Pascolo, S.. Vaccines against COVID-19: Priority to mRNA-based formulations. Cells. 2021;10(10):Article 2716. https://doi.org/10.3390/cells10102716DOIGOOGLE SCHOLAR
  51. 51.Ramírez-Cortés, F.; Ménová, P.. Hepatocyte targeting via the asialoglycoprotein receptor. RSC Medicinal Chemistry. 2025;16(2):525–544. https://doi.org/10.1039/D4MD00652FDOIGOOGLE SCHOLAR
  52. 52.Richner, J. M.; Himansu, S.; Dowd, K. A.; Butler, S. L.; Salazar, V.; Fox, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114–11250000000000. https://doi.org/10.1016/j.cell.2017.02.017DOIGOOGLE SCHOLAR
  53. 53.Riley, R. S.; Kashyap, M. V.; Billingsley, M. M.; White, B.; Alameh, M.-G.; Bose, S. K. et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Science Advances. 2021;7(3):Article eaba1028. https://doi.org/10.1126/sciadv.aba1028DOIGOOGLE SCHOLAR
  54. 54.Rouf, N. Z.; Biswas, S.; Tarannum, N.; Oishee, L. M.; Muna, M. M.. Demystifying mRNA vaccines: An emerging platform at the forefront of cryptic diseases. RNA Biology. 2022;19(1):386–410. https://doi.org/10.1080/15476286.2022.2055923DOIGOOGLE SCHOLAR
  55. 55.Sahin, U.; Karikó, K.; Türeci, Ö.. mRNA-based therapeutics—Developing a new class of drugs. Nature Reviews. Drug Discovery. 2014;13(10):759–780. https://doi.org/10.1038/nrd4278DOIGOOGLE SCHOLAR
  56. 56.Sedic, M.; Senn, J. J.; Lynn, A.; Laska, M.; Smith, M.; Platz, S. J. et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Veterinary Pathology. 2018;55(2):341–354. https://doi.org/10.1177/0300985817738095DOIGOOGLE SCHOLAR
  57. 57.Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S. Y.; Sood, A. K.; Hua, S.. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 2015;6:Article 286. https://doi.org/10.3389/fphar.2015.00286DOIGOOGLE SCHOLAR
  58. 58.Sharma, V. K.; Watts, J. K.. Oligonucleotide therapeutics: Chemistry, delivery and clinical progress. Future Medicinal Chemistry. 2015;7(16):2221–2242. https://doi.org/10.4155/fmc.15.144DOIGOOGLE SCHOLAR
  59. 59.Soenen, S. J. H.; Brisson, A. R.; De Cuyper, M.. Addressing the problem of cationic lipid-mediated toxicity: The magnetoliposome model. Biomaterials. 2009;30(22):3691–3701. https://doi.org/10.1016/j.biomaterials.2009.03.040DOIGOOGLE SCHOLAR
  60. 60.Stephenson, M. L.; Zamecnik, P. C.. Proceedings of the National Academy of Sciences of the United States of America. 1978;75(1):285–288. https://doi.org/10.1073/pnas.75.1.285DOIGOOGLE SCHOLAR
  61. 61.Toh, Y.-C.; Lim, T. C.; Tai, D.; Xiao, G.; van Noort, D.; Yu, H.. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab on a Chip. 2009;9(14):2026–2035. https://doi.org/10.1039/b900912dDOIGOOGLE SCHOLAR
  62. 62.Tuller, T.; Zur, H.. Multiple roles of the coding sequence 5′ end in gene expression regulation. Nucleic Acids Research. 2015;43(1):13–28. https://doi.org/10.1093/nar/gku1313DOIGOOGLE SCHOLAR
  63. 63.Vader, P.; Mol, E. A.; Pasterkamp, G.; Schiffelers, R. M.. Extracellular vesicles for drug delivery. Advanced Drug Delivery Reviews. 2016;106(A):148–156. https://doi.org/10.1016/j.addr.2016.02.006DOIGOOGLE SCHOLAR
  64. 64.Van Hoecke, L.; Roose, K.. How mRNA therapeutics are entering the monoclonal antibody field. Journal of Translational Medicine. 2019;17(1):Article 54. https://doi.org/10.1186/s12967-019-1804-8DOIGOOGLE SCHOLAR
  65. 65.Warrier, D. U.; Desai, H. R.; Singh, K. H.; Shinde, U. A.. Solid lipid nanoparticle-based drug delivery for lung cancer. In Handbook of lung targeted drug delivery systems. CRC Press.. 2021;303–323. https://doi.org/10.1201/9781003046547-21DOIGOOGLE SCHOLAR
  66. 66.Watson, J. D.; Crick, F. H.. A structure for ADN. Nature. 1953;171(4356):737–738. https://doi.org/10.1038/171737a0DOIGOOGLE SCHOLAR
  67. 67.Wolff, J. A.; Malone, R. W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A. et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468. https://doi.org/10.1126/science.1690918DOIGOOGLE SCHOLAR
  68. 68.Wu, L.; Li, X.; Qian, X.; Wang, S.; Liu, J.; Yan, J.. Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. Vaccines. 2024;12(2):Article 186. https://doi.org/10.3390/vaccines12020186DOIGOOGLE SCHOLAR
  69. 69.Zheng, C.; Baum, B. J.; Iadarola, M. J.; O’Connell, B. C.. Genomic integration and gene expression by a modified adenoviral vector. Nature Biotechnology. 2000;18(2):176–180. https://doi.org/10.1038/72628DOIGOOGLE SCHOLAR

Cite this article

SELECT FORMAT

Shinde, Y., Sharma, T. P., Shaha, A., Chaudhari, R., Rajeghorpade, R., Talele, D., & Talele, C. (2026). Metabolism of mRNA Therapeutics: Insights into Pharmacokinetics and Toxicology. International Journal of Pharmaceutical Investigation, 16(2), 517–522. https://doi.org/10.5530/ijpi.20260539